

Notes on Zika Manufacturing Capacity

Diane Singhroy, PhD.

Scientific and Technical Advisor at Knowledge Ecology International (KEI)

February 16, 2017

On February 1st, 2016, the World Health Organization (WHO) had declared the Zika virus to be a “public health emergency of international concern”.¹ Only 9 months earlier the first reports of Zika virus being transmitted locally, that is via mosquitoes, were emerging from Brazil.² The Zika virus carrying mosquitoes had quickly reached American shores and by July 2016 the CDC had linked four new Zika cases to local mosquito transmission in Florida.³ To date there have been 220 locally acquired cases and 4781 travel-associated cases reported in the US.⁴ In American territories (ie: Puerto Rico, American Samoa and the US Virgin Islands) the number of locally acquired infections are a staggering 36,498 cases.

The Zika virus is a pathogen from the *Flaviviridae* family. *Flaviviridae* viruses can cause serious illness and include yellow fever virus, Japanese encephalitis virus, hepatitis C virus (HCV) and the emerging dengue virus. Although mosquitoes are the primary vector for the Zika virus, it can also be transmitted from person-to-person through sexual contact or from mother-to-child *in utero*. About 80% of individuals infected by Zika are asymptomatic and in rare instances they can develop Guillain-Barré syndrome.⁵ When symptoms do occur they present as low grade fever, joint pain, rash, headache and conjunctivitis (pinkeye).⁶ However, the most devastating consequence of this viral infection is the development of microcephaly in babies born from women who contracted Zika while pregnant. This birth defect often results in infants having smaller or abnormal brains and partially collapsed skulls that can greatly affect the child's proper development, induce seizures, cause intellectual disabilities and limit motor skills.

Currently there are no treatments or vaccines for Zika. However, like HCV, Zika has a positive-sense single-stranded RNA genome and requires an RNA-dependent RNA polymerase (RdRp) to complete its replication cycle. HCV and Zika virus share 80% RdRp sequence homology and scientists found that sofosbuvir inhibited the Zika replication in various cell types.⁷ Sofosbuvir could be a promising therapeutic candidate for Zika, but ultimately developing a Zika vaccine is key to curbing the epidemic. Currently there are at least 28 entities working on different Zika vaccine candidates that are at various stages of development (table 1). The US government is funding the development of 4 candidates through the National Institutes of Allergy and Infectious Diseases (NIAID) and through the Department of Defense (DoD). The Army's ZPIV vaccine and the NIAID DNA vaccine both

¹ <http://www.who.int/emergencies/zika-virus/history/en/>

² http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=30075=en%20%28accessed%202016%29

³ <https://www.cdc.gov/media/releases/2016/p0729-florida-zika-cases.html>

⁴ <https://www.cdc.gov/zika/intheus/maps-zika-us.html> (accessed Feb 9)

⁵ Lin HH, Huang LM, Wu SC. Zika Virus Molecular Biology and Perspectives for Vaccine Development: A Review. *J Nurs Res.* 2017 Feb;25(1):3-6.

⁶ <https://www.cdc.gov/zika/symptoms/symptoms.html>

⁷ Sacramento CQ *et al.* The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. *Sci Rep.* 2017 Jan 18;7:40920.

exhibited very promising results in preclinical and animal studies and are currently undergoing clinical trials.

Table 1: Zika virus vaccine candidates (from Lin *et al.*)⁵

| Developers | Platform | Antigen | Trial phase |
|------------------------------------------------------|--------------------------------------|--------------------------|--------------|
| Bharat Biotech | Inactivated | Whole virus | Non-clinical |
| Bio-Manguinhos / Fiocruz | Recombinant vaccine vector | PrM/E and PrM/E/NS1 | Non-clinical |
| | Inactivated | Whole virus | |
| | Recombinant subunit (non VLP) | E protein | |
| | Recombinant subunit VLP (non-fusion) | E protein | |
| Butantan | Inactivated | Whole virus | Non-clinical |
| | Live, attenuated target organism | Whole virus | |
| GeneOne/InOvivo | DNA | prME | Phase 1 |
| GeoVax/University of Georgia/CDC | Recombinant viral vector | PrME+NS1 | Non-clinical |
| Hawaii Biotech, Inc. | Recombinant subunit (non VLP) | E protein | Non-clinical |
| Institut Pasteur Shanghai, Shanghai, China | Recombinant subunit VLP (non-fusion) | | Non-clinical |
| Institut Pasteur, Paris, France | Recombinant vaccine vector | preME | Non-clinical |
| NewLink Genetics | Inactivated | All structural antigens | Non-clinical |
| | Recombinant subunit VLP (fusion) | prM-E | |
| NIAID Intramural | Live, attenuated target organism | ZIKV prME | Non-clinical |
| | Live, attenuated target organism | ZIKV full genome | |
| Protein Sciences/Sinergium Biotech/ Lab Liomont /UMN | Recombinant subunit (non VLP) | E protein | Non-clinical |
| Replikin, Ltd and LLC | Peptide | Synthetic peptides | Non-clinical |
| Sanofi Pasteur | Recombinant viral vector | Zika structural proteins | Non-clinical |
| Themis Bioscience GmbH | Recombinant vaccine vector | | Non-clinical |
| Valera (Moderna) | mRNA | prME | Non-clinical |
| Valneva | Inactivated | Whole virus | Non-clinical |
| Vaxart | Recombinant vaccine vector | Env+ | Non-clinical |
| VRC/NIAID | DNA | PrM and E | Phase 1 |
| WRRAIR / BIDMC/Harvard / NIAID / Sanofi Pasteur | Inactivated | Whole virus | Non-clinical |

Note. CDC= Centers for Disease Control and Prevention; NIAID= National Institute of Allergy and Infectious Diseases; UMN= University of Minnesota; VRC= Vaccine Research Center; WRRAIR=; BIDMC= Beth Israel Deaconess Medical Center; VLP=; prM= pre-membrane; E= envelope genes; NS1= NS1 influenza protein (a viral nonstructural protein); ZIKV=Zika virus; Env= envelope.

The DoD candidate is a purified inactivated virus (PIV) and the authors describe how to produce the vaccine in their August 2016 Nature publication entitled “Vaccine protection against Zika Virus from Brazil”.

“The ZIKV purified inactivated virus (PIV, also termed ZPIV) vaccine was produced at the Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD, USA. The PIV vaccine was based on the Puerto Rican PRVABC59 isolate, which was obtained from the US Centers for Disease Control and Prevention, Fort Collins, CO, USA. The Vero cells used for passage and vaccine production were a derivative of a certified cell line manufactured at The Salk Institute, Swiftwater, PA. After inoculation, virus was collected on days 5 and 7, clarified by centrifugation and depth filter (0.45–0.2 μ m), and treated with benzonase. The viral harvest was concentrated with an ultrafilter followed by purification using Captocore chromatography resin. The purified ZIKV was then inactivated with formalin (0.05%) at 22 °C for 7 days. Following inactivation, formalin was removed by dialysis, and the antigen concentration was adjusted. The final PIV vaccine was assessed for

infectivity by passage in Vero cells followed by plaque assays to demonstrate inactivation.”⁸

This protocol is based on one that was developed by the army to produce IXIARO, an inactivated whole-virus Japanese encephalitis vaccine. Vaccines based on purifying a microorganism followed by inactivating them, are among the oldest types of vaccines we still use.

The concept of using inactivated pathogens as prophylaxis was first tried in 1886 by killing cholera virus and immunizing pigeons.⁹ The earliest immunization attempt in humans with an inactivated pathogen was in 1897 using typhoid, but the key element to routinely producing such vaccines *in vitro* was discovered by Drs. Enders and Weller in developing techniques for growing poliovirus in cell culture.⁹ They were awarded a Nobel prize in 1954 for their work and since, the underlying procedures to developing and producing inactivated viral vaccines haven't derived much from the foundations Enders and Weller established. Though today, techniques are more efficient and the resulting vaccines have a significantly better safety profiles due to more robust inactivation methods.

Generally, the biggest roadblock to developing an inactivated vaccine, is finding a reliable way to grow stocks of the virus in the lab. This would involve finding the proper organism to grow the virus so that it can be harvested, inactivated and turned into a vaccine. Ideally, researchers would try to grow the virus in a cell line, since this is the most cost effective solution. Unfortunately some viruses are difficult to grow in cell culture rendering the whole process very time consuming and tedious. This is the case for influenza, for example, since it has to be manufactured in fertilized chicken eggs! Fortunately ZPIV can be grown in a standard cell line called vero cells.

Because these techniques are straightforward and relatively standard in a virologist's toolbox, many drug companies would be capable of manufacturing inactivated whole virus vaccines, provided they had access to the particular parameters needed to effectively produce the vaccine and test its inactivation. In the United States there are at least 158 companies and facilities that manufacture different types of vaccines (Table 2).

Table 2: Vaccine companies in the USA (adapted from biopharmguy)¹⁰

| Company/ Facilities | Location | Specialty |
|----------------------|-----------------|----------------------------------------------------------------------------------------------------------|
| IGNITE Immunotherapy | Alameda, CA | Oncolytic Virus Vaccines |
| Dynavax Technologies | Berkeley, CA | DNA Therapeutics |
| Gritstone Oncology | Emeryville, CA | Personalized cancer vaccines |
| Novartis Diagnostics | Emeryville, CA | Small Molecules, Vaccines, Biologics |
| Entest Biomedical | La Mesa, CA | Immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine. |
| CardioVax | Los Angeles, CA | Small Molecules |

⁸ Larocca RA et al. Vaccine protection against Zika virus from Brazil. *Nature*. 2016 Aug 25;536(7617):474-8.

⁹ Barbara Sanders, Martin Koldijk, Hanneke Schuitemaker. *Vaccine Analysis: Strategies, Principles, and Control*. Chapter: Inactivated Viral Vaccines. pp 45-80. Springer-Verlag. 2015

¹⁰ <http://biopharmguy.com/links/company-by-location-vaccines.php>

| | | |
|---------------------------------|--------------------|-----------------------------------------------|
| ImmunoScience | Pleasanton, CA | HIV diagnostic, vaccine |
| Juvaris | Pleasanton, CA | Vaccines |
| Tolerion | Portola Valley, CA | DNA Vaccines for Autoimmune Disorders |
| Bavarian Nordic | Redwood City, CA | Vaccines |
| PaxVax | Redwood City, CA | Vaccines |
| Activate Immunotherapy | San Diego, CA | Biologic Vaccines, small molecules |
| Adamis Pharmaceuticals | San Diego, CA | Specialty Pharmaceuticals |
| BioMedicure | San Diego, CA | Cancer Vaccines, Cancer Research Products |
| Inovio Pharmaceuticals | San Diego, CA | DNA Vaccines |
| MabVax Therapeutics | San Diego, CA | Small Molecules |
| MediGene | San Diego, CA | Small Molecules, Oncolytic Viruses |
| Novartis | San Diego, CA | Small Molecules, Vaccines, Biologics |
| PaxVax | San Diego, CA | Vaccines |
| Pfenex | San Diego, CA | Biosimilars, Vaccines |
| Polynoma | San Diego, CA | Melanoma Vaccine |
| Vical | San Diego, CA | DNA Delivery, Vaccines |
| Galena Biopharma | San Ramon, CA | Cancer Vaccines |
| Meissa Vaccines | South SF, CA | Vaccines |
| Pfizer | South SF, CA | Biologics |
| SutroVax | South SF, CA | Conjugate vaccines and protein-based vaccines |
| Vaxart | South SF, CA | Oral Vaccines |
| Altravax | Sunnyvale, CA | Vaccines |
| Novartis | Vacaville, CA | Small Molecules, Vaccines, Biologics |
| ImmunoCellular Therapeutics | Woodland Hills, CA | Cancer Antigen Vaccines |
| Sandoz (Novartis) | Broomfield, CO | Small Molecules, Vaccines, Biologics |
| Vivaldi Biosciences | Fort Collins, CO | Live-Attenuated Flu Vaccines |
| CellDex Therapeutics | Branford, CT | Small Molecules, Biologics, Vaccines |
| Protein Sciences | Meriden, CT | Biologics, Vaccines |
| EpitoGenesis | Storrs, CT | Vaccine Delivery Technologies |
| Nanotherapeutics | Alachua, FL | Small Molecules, Bone Grafts, Vaccines |
| TapImmune | Jacksonville, FL | Vaccines |
| Aurora Biopharma | Miami, FL | Immunotherapeutic treatments |
| Opko Health | Miami, FL | Biologics, Vaccines, Diagnostics, etc |
| GeoVax | Atlanta, GA | Vaccines |
| Inhibikase Therapeutics | Atlanta, GA | Therapeutic Vaccines |
| Novartis | Duluth, GA | Small Molecules, Vaccines, Biologics |
| GeneCure Biotechnologies | Norcross, GA | Gene Transfer Technology |
| CSL Behring | Bradley, IL | Biologics |
| Pfizer | Andover, MA | Small Molecules, Vaccines, Biologics |
| Antera Therapeutics | Boston, MA | Peanut Allergy Preventative |
| Matrivax Research & Development | Boston, MA | Encapsulation of Bacterial Pathogens |

| | | |
|-----------------------------------------|-------------------|----------------------------------------------------------------------------------|
| Merck | Boston, MA | Small Molecules, Vaccines, Biologics |
| TremRx | Boston, MA | Vaccines |
| Affinivax | Cambridge, MA | Vaccine Discovery Technology |
| Aurora Biopharma | Cambridge, MA | Immunotherapeutic treatments |
| Genocea Bioscience | Cambridge, MA | Vaccines |
| Gritstone Oncology | Cambridge, MA | Personalized cancer vaccines |
| ImmusanT | Cambridge, MA | Peptide therapeutic vaccine |
| Inhibikase Therapeutics | Cambridge, MA | Therapeutic Vaccines |
| Medvax Technologies | Cambridge, MA | Cancer vaccines |
| Neon Therapeutics | Cambridge, MA | Vaccines & T cell therapies |
| Novartis | Cambridge, MA | Small Molecules, Vaccines, Biologics /Diagnostics |
| Sanofi Pasteur | Cambridge, MA | Biologics, Vaccines |
| Sanofi Pasteur | Cambridge, MA | Biologics, Vaccines |
| Vaxxas Nanopatch | Cambridge, MA | Vaccine patch delivery system |
| VBI Vaccines | Cambridge, MA | Vaccine Development |
| Sanofi Pasteur | Canton, MA | Biologics, Vaccines |
| Alopexx Vaccine (Alopexx) | Concord, MA | Vaccine |
| Celldex Therapeutics | Fall River, MA | Small Molecules, Biologics, Vaccines |
| Berg | Framingham, MA | Small Molecules |
| Agenus | Lexington, MA | Biologics |
| Xenetic Biosciences | Lexington, MA | biologic drugs, novel oncology therapeutics and vaccinations |
| Celldex Therapeutics | Needham, MA | Small Molecules, Biologics, Vaccines |
| OncoPep | North Andover, MA | Cancer vaccine |
| Selecta Biosciences | Watertown, MA | Synthetic Vaccine Particles |
| Antigen Express (Generex Biotechnology) | Wellesley, MA | Biologics |
| Opko Health | Woburn, MA | Biologics, Vaccines, Diagnostics, etc |
| PharmAthene | Annapolis, MD | Biological and Chemical Weapon Defense |
| Emergent BioSolutions | Baltimore, MD | Biologic Vaccines |
| PathoVax | Baltimore, MD | HPV vaccine |
| Sanofi Pasteur | Bethesda, MD | Biologics, Vaccines |
| Biofactura | Frederick, MD | Biosimilar production technology, smallpox drug |
| Biological Mimetics | Frederick, MD | Vaccines, Therapeutic Antibodies Discovered by "Immune Dampening and Refocusing" |
| Medigen | Frederick, MD | Cancer & Infectious disease vaccines, contract services |
| MedImmune (AstraZeneca) | Frederick, MD | Small Molecules, Vaccines, Biologics |
| Altimune | Gaithersburg, MD | Biologics, Vaccines, Drug Delivery |
| Emergent BioSolutions | Gaithersburg, MD | Biologic Vaccines |
| MedImmune (AstraZeneca) | Gaithersburg, MD | Small Molecules, Vaccines, Biologics |
| Valneva | Gaithersburg, MD | Vaccines (Marketing) |
| Wellstat Group | Gaithersburg, MD | Group of Many Small Drug and Diagnostic Companies |
| Biologics Resources | Germantown, MD | Vaccines, Biologics |

| | | |
|----------------------------|----------------------------|--------------------------------------------------|
| Neuralstem | Germantown, MD | Stem Cell Technology |
| SynAm Vaccine | Germantown, MD | Pneumococcal vaccine |
| Emergent BioSolutions | Rockville, MD | Biologic Vaccines |
| GlaxoSmithKline | Rockville, MD | Small Molecules, Vaccines, Biologics |
| Immunomic Therapeutics | Rockville, MD | Vaccines (Lysosomal Associated Membrane Protein) |
| Integrated BioTherapeutics | Rockville, MD | Vaccines |
| Sanaria | Rockville, MD | Malaria Vaccine, Reagents for malaria research |
| NanoBio | Ann Arbor, MI | Topical, Mucosal Vaccines and Therapies |
| Emergent BioSolutions | Lansing, MI | Biologic Vaccines |
| GlaxoSmithKline | St. Louis, MO | Small Molecules, Vaccines, Biologics |
| Immunophotonics | St. Louis, MO | Autologous cancer vaccine |
| Sequoia Sciences | St. Louis, MO | Antibacterial Small Molecules, Vaccines for UTI |
| Takeda | Bozeman, MT | Biologics, Vaccines |
| Heat Biologics | Chapel Hill, NC | Therapeutic Vaccines |
| Liquidia Technologies | Morrisville, NC | Particle-Based Therapies |
| GlaxoSmithKline | Research Triangle Park, NC | Small Molecules, Vaccines, Biologics |
| Annias Immunotherapeutics | RTP, NC | Therapeutic Brain Tumor Vaccine |
| Pfizer | Sanford, NC | Small Molecules, Vaccines, Biologics |
| Sandoz (Novartis) | Wilson, NC | Small Molecules, Vaccines, Biologics |
| NovaDigm Therapeutics | Grand Forks, ND | Fungal & Bacterial Infection Vaccines |
| Novartis | Lincoln, NE | Small Molecules, Vaccines, Biologics |
| VaxInnate | Cranbury, NJ | Vaccines |
| Novartis | East Hanover, NJ | Small Molecules, Vaccines, Biologics |
| Sandoz (Novartis) | East Hanover, NJ | Small Molecules, Vaccines, Biologics |
| Celldex Therapeutics | Hampton, NJ | Small Molecules, Biologics, Vaccines |
| Pfizer | Madison, NJ | Small Molecules, Vaccines, Biologics |
| Advaxis | North Brunswick, NJ | Listeria Vaccine |
| GlaxoSmithKline | Parsippany, NJ | Small Molecules, Vaccines, Biologics |
| Novartis | Parsippany, NJ | Small Molecules, Vaccines, Biologics |
| Emergent BioSolutions | Princeton, NJ | Biologic Vaccines |
| Sandoz (Novartis) | Princeton, NJ | Small Molecules, Vaccines, Biologics |
| Merck | Rahway, NJ | Small Molecules, Vaccines, Biologics |
| Akorn | Somerset, NJ | Biologics, Vaccines |
| Agilvax | Albuquerque, NM | VLP vaccines |
| United Biomedical | Hauppauge, NY | Monoclonals, Vaccines, Biosimilars |
| DanDrit Biotechnology | New York, NY | Cancer Vaccines |
| Intellect Neurosciences | New York, NY | Vaccines Discovery platform |
| Pfizer | New York, NY | Small Molecules, Vaccines, Biologics |
| Pfizer | Pearl River, NY | Small Molecules, Vaccines, Biologics |
| Alpha-1 Biologics | Stony Brook, NY | small molecules, peptides, diagnostic, vaccine |
| Codagenix | Stony Brook, NY | Live-attenuated vaccine design technology |

| | | |
|-----------------------------------------|----------------------|-----------------------------------------------------------|
| TechnoVax | Tarrytown, NY | VLP vaccines |
| Najit Technologies | Beaverton, OR | Vaccines |
| TomegaVax | Beaverton, OR | Cytomegalovirus-based vaccines |
| UbiVac | Portland, OR | Vaccine/Immunotherapy |
| GlaxoSmithKline | Collegeville, PA | Small Molecules, Vaccines, Biologics |
| Pfizer | Collegeville, PA | Small Molecules, Vaccines, Biologics |
| GlaxoSmithKline | Conshohocken, PA | Small Molecules, Vaccines, Biologics |
| Immunotope | Doylestown, PA | Immunotherapy for cancer and chronic viral infections |
| Immunomic Therapeutics | Hershey, PA | Vaccines (Lysosomal Associated Membrane Protein) |
| CSL Behring | King of Prussia, PA | Biologics |
| GlaxoSmithKline | King of Prussia, PA | Small Molecules, Vaccines, Biologics |
| Merck | Lansdale, PA | Small Molecules, Vaccines, Biologics |
| GlaxoSmithKline | Marietta, PA | Small Molecules, Vaccines, Biologics |
| GlaxoSmithKline | Montgomery, PA | Small Molecules, Vaccines, Biologics |
| Merck | North Wales, PA | Small Molecules, Vaccines, Biologics |
| Avax Technologies | Philadelphia, PA | Vaccines |
| GlaxoSmithKline | Philadelphia, PA | Small Molecules, Vaccines, Biologics |
| Inovio Pharmaceuticals | Plymouht Meeting, PA | DNA Vaccines |
| Molecular Targeting Technologies (MTTI) | West Chester, PA | Diagnostics & Therapeutics |
| Berg | Nashville, TN | Small Molecules |
| Vitruvian Biomedical | Addison, TX | Alzheimer's vaccine, diagnostics, enzyme-detection device |
| Bellicum Pharmaceuticals | Houston, TX | Cellular Therapy |
| Merck | Elkton, VA | Small Molecules, Vaccines, Biologics |
| Cascadian Therapeutics | Seattle, WA | Small Molecules & Immunotherapy |
| EpiThany | Seattle, WA | Cancer Vaccines |
| Etubics | Seattle, WA | Targeted immunotherapies and vaccine products |
| Immune Design | Seattle, WA | DNA Vaccines |
| TRIA Biosciences | Seattle, WA | Vaccines |
| FluGen | Madison, WI | Vaccines & Adjuvants |
| Madison Vaccines | Madison, WI | DNA vaccines, companion diagnostic |